红鹰彩票软件,光大彩票登录官方平台,乐鱼官方网站在线登录网页,澳门网上真人注册,凤凰彩票手机,凤凰彩票注册,大小单双彩票app平台网站

Recently, C&D Emerging Industry Equity Investment has received several industry awards. It was ranked NO. 3 on the “2025 Top 100 Industrial Investors” list released by FOF Weekly, and was named one of the “Top 50 Best Corporate Venture Investors in China for 2024” by CVINFO. In addition, several of its portfolio companies—including Impact Therapeutics, Pins Medical, Aidite, Narwal Robotics, SJ SEMI, Kaida Hengye, and AMiner—also received multiple awards on the CVINFO list. In addition, in the “2024 China Best Institutional LP List” released by Chulei Research Institute, C&D Emerging Industry Equity Investment was recognized as one of the “Top 20 Best Institutional LPs in China for 2024” and “Top 10 Best Direct Investment LPs in China for 2024.”

C&D Emerging Industry Equity Investment will remain committed to the mission of "exploring new values for more emerging enterprises to achieve better development", continue to provide unwavering assistance to exceptional fund managers and entrepreneurs, actively promote industrial upgrading and structural optimization, and inject momentum into the development of emerging industries.